{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:31:55Z","timestamp":1793410315817,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":2040,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1017\/s1041610218001400","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T11:22:33Z","timestamp":1541503353000},"page":"815-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of visual hallucinations in dementia and Parkinson\u2019s disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Peter","family":"Swann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610218001400_bb0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610218001400_bb0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study","volume":"48","author":"Aarsland","year":"2000","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610218001400_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1017\/S1041610218001400_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","article-title":"Dopamine agonists in the treatment of early Parkinson\u2019s disease: a meta-analysis","volume":"15","author":"Baker","year":"2009","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1017\/S1041610218001400_bb0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4088\/JCP.v62n0110","article-title":"The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer\u2019s disease: persistence and new cases over 1 year of follow-up","volume":"62","author":"Ballard","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0035","first-page":"CD003476","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease","volume":"25","author":"Ballard","year":"2006","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610218001400_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1176\/appi.ajp.2015.15010130","volume":"173","author":"Ballard","year":"2016","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"The Lancet Neurology"},{"key":"10.1017\/S1041610218001400_bb0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","article-title":"Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey","volume":"70","author":"Barnes","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1099-1166(200002)15:2<99::AID-GPS82>3.0.CO;2-5","article-title":"Delusions and hallucinations in Alzheimer\u2019s disease: prevalence and clinical correlates","volume":"15","author":"Bassiony","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0060","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.psy.44.5.388","article-title":"Delusions and hallucinations in Alzheimer\u2019s disease: review of the brain decade","volume":"44","author":"Bassiony","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1017\/S1041610218001400_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease","volume":"25","author":"Bergman","year":"2002","journal-title":"Clinical Neuropharmacology"},{"key":"10.1017\/S1041610218001400_bb0070","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WNF.0000000000000254","article-title":"Successful use of escitalopram for the treatment of visual hallucinations in patients with Parkinson disease","volume":"40","author":"Bergman","year":"2017","journal-title":"Clinical Neuropharmacology"},{"key":"10.1017\/S1041610218001400_bb0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1060028017693029","article-title":"Pimavanserin: a novel antipsychotic for Parkinson\u2019s disease psychosis","volume":"51","author":"Bozymski","year":"2017","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1017\/S1041610218001400_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biological Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1586\/17512433.2014.966814","article-title":"Novel pharmaceuticals in the treatment of psychosis in Parkinson\u2019s disease","volume":"7","author":"Broadstock","year":"2014","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1017\/S1041610218001400_bb0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Current Medical Research and Opinion"},{"key":"10.1017\/S1041610218001400_bb0095","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease","volume":"21","author":"Burn","year":"2006","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/YCT.0000000000000432","article-title":"Use of electroconvulsive therapy in dementia-related agitation: a case series","volume":"33","author":"Burton","year":"2017","journal-title":"The Journal of ECT"},{"key":"10.1017\/S1041610218001400_bb0105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/CIA.S4250","article-title":"Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: a meta-analysis","volume":"3","author":"Campbell","year":"2008","journal-title":"Clinical Interventions in Aging"},{"key":"10.1017\/S1041610218001400_bb0110","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00415-015-7687-6","article-title":"On visual hallucinations and cortical networks: a trans-diagnostic review","volume":"262","author":"Carter","year":"2015","journal-title":"Journal of Neurology"},{"key":"10.1017\/S1041610218001400_bb0115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fnl.13.19","article-title":"Advances in the treatment of visual hallucinations in neurodegenerative diseases","volume":"8","author":"Collerton","year":"2013","journal-title":"Future Neurology"},{"key":"10.1017\/S1041610218001400_bb0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/NDT.S108948","article-title":"Update on the treatment of Parkinson\u2019s disease psychosis: role of pimavanserin","volume":"13","author":"Combs","year":"2017","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1017\/S1041610218001400_bb0125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1017\/S1041610218001400_bb0130","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1017\/S0033291717003257","article-title":"Non-pharmacological interventions for Lewy body dementia: a systematic review","volume":"48","author":"Connors","year":"2017","journal-title":"Psychological Medicine"},{"key":"10.1017\/S1041610218001400_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00002512-199507020-00002","article-title":"Adjunctive therapy in patients with Alzheimer\u2019s disease. A practical approach","volume":"7","author":"Corey-Bloom","year":"1995","journal-title":"Drugs & Aging"},{"key":"10.1017\/S1041610218001400_bb0140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1017\/S1041610218001400_bb0145","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1543-5946(05)80020-0","article-title":"Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer\u2019s disease: a 26-week, multicenter, open-label study","volume":"3","author":"Cummings","year":"2005","journal-title":"The American Journal of Geriatric Pharmacotherapy"},{"key":"10.1017\/S1041610218001400_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048636","article-title":"Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies","volume":"13","author":"Cummings","year":"2002","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610218001400_bb0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study","volume":"25","author":"De Deyn","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1017\/S1041610218001400_bb0165","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","article-title":"Course of psychiatric symptoms and global cognition in early Parkinson disease","volume":"83","author":"de la Riva","year":"2014","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0170","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/089198879500800104","article-title":"Neuroleptic treatment of agitation and psychosis in dementia","volume":"8","author":"Devanand","year":"1995","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1017\/S1041610218001400_bb0175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.10450","article-title":"Coping strategies for visual hallucinations in Parkinson\u2019s disease","volume":"18","author":"Diederich","year":"2003","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S0033291714000816","article-title":"Prodromal dementia with Lewy bodies","volume":"45","author":"Donaghy","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1017\/S1041610218001400_bb0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","article-title":"Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania","volume":"15","author":"Dotchin","year":"2009","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1017\/S1041610218001400_bb0190","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0195","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/WNL.47.6.1608-b","article-title":"Ondansetron treatment of L-dopa-induced psychosis","volume":"47","author":"Eichhorn","year":"1996","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease","volume":"12","author":"Ellis","year":"2000","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1017\/S1041610218001400_bb0205","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1017\/S1041610218001400_bb0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"The Lancet. Neurology"},{"key":"10.1017\/S1041610218001400_bb0215","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/ene.13376","article-title":"The role of neurotransmitters in the development of Parkinson\u2019s disease-related psychosis","volume":"24","author":"Factor","year":"2017","journal-title":"European Journal of Neurology"},{"key":"10.1017\/S1041610218001400_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euroneuro.2017.01.002","article-title":"Benefits and harms of atypical antipsychotics for agitation in adults with dementia","volume":"27","author":"Farlow","year":"2017","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1017\/S1041610218001400_bb0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson\u2019s disease","volume":"289","author":"F\u00e9nelon","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1017\/S1041610218001400_bb0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain: A Journal of Neurology"},{"key":"10.1017\/S1041610218001400_bb0235","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","article-title":"Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture. Results from a double blind clinical-polysomnography study","volume":"119","author":"Fernandez","year":"2009","journal-title":"International Journal of Neuroscience"},{"key":"10.1017\/S1041610218001400_bb0240","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/122.7.1247","article-title":"The perceptual consequences of visual loss: \u201cpositive\u201d pathologies of vision","volume":"122","author":"Ffytche","year":"1999","journal-title":"Brain: A Journal of Neurology"},{"key":"10.1017\/S1041610218001400_bb0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer\u2019s disease in outpatients treated with donepezil","volume":"19","author":"Finkel","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0250","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson\u2019s disease","volume":"344","author":"Ford","year":"1994","journal-title":"The Lancet"},{"key":"10.1017\/S1041610218001400_bb0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.24942","article-title":"Melperone is ineffective in treating Parkinson\u2019s disease psychosis","volume":"27","author":"Friedman","year":"2012","journal-title":"Movement Disorders"},{"key":"10.1017\/S1041610218001400_bb0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behavioural Neurology"},{"key":"10.1017\/S1041610218001400_bb0265","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease","volume":"21","author":"Friedman","year":"2006","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1179\/1743132814Y.0000000418","article-title":"Risk factors for visual hallucinations in patients with Parkinson\u2019s disease","volume":"37","author":"Gama","year":"2015","journal-title":"Neurological Research"},{"key":"10.1017\/S1041610218001400_bb0275","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0280","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.161.8.1099","article-title":"Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients","volume":"161","author":"Han","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610218001400_bb0285","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jamda.2005.04.003","article-title":"The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer\u2019s disease","volume":"6","author":"Hatoum","year":"2005","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610218001400_bb0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4140\/TCP.n.2006.563","article-title":"Dementia with Lewy bodies: therapeutic opportunities and pitfalls","volume":"21","author":"Henriksen","year":"2006","journal-title":"The Consultant Pharmacist: The Journal of the American Society of Consultant Pharmacists"},{"key":"10.1017\/S1041610218001400_bb0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00019442-200506000-00012","article-title":"Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials","volume":"13","author":"Herrmann","year":"2005","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0300","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11920-999-0014-0","article-title":"Neuropsychiatric aspects of dementia with Lewy bodies","volume":"1","author":"Hirono","year":"1999","journal-title":"Current Psychiatry Reports"},{"key":"10.1017\/S1041610218001400_bb0305","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"Ikeda","year":"2015","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1017\/S1041610218001400_bb0310","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/bjo.2006.104604","article-title":"Contrast sensitivity and visual hallucinations in patients referred to a low vision rehabilitation clinic","volume":"91","author":"Jackson","year":"2007","journal-title":"The British Journal of Ophthalmology"},{"key":"10.1017\/S1041610218001400_bb0315","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","article-title":"Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel","volume":"62","author":"Kales","year":"2014","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610218001400_bb0320","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/WNN.0000000000000008","article-title":"Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort","volume":"26","author":"Kertesz","year":"2013","journal-title":"Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology"},{"key":"10.1017\/S1041610218001400_bb0325","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0330","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1017\/S1041610214002580","article-title":"Psychotic symptoms in frontotemporal dementia: a diagnostic dilemma?","volume":"27","author":"Landqvist Wald\u00f6","year":"2015","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610218001400_bb0335","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jns.2017.06.011","article-title":"Psychosis in Parkinson\u2019s disease: from the soft signs to the hard science","volume":"379","author":"Lenka","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1017\/S1041610218001400_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease","volume":"19","author":"Leroi","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0345","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119","article-title":"Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials","volume":"205","author":"Livingston","year":"2014","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"key":"10.1017\/S1041610218001400_bb0350","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.41.6.906","article-title":"Alzheimer\u2019s disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates","volume":"41","author":"Lopez","year":"1991","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0355","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1017\/S1041610218001400_bb0360","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.4088\/JCP.16r11119","article-title":"The US food and drug administration\u2019s perspective on the new antipsychotic pimavanserin","volume":"78","author":"Mathis","year":"2017","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0365","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hup.2286","article-title":"Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Matsuda","year":"2013","journal-title":"Human Psychopharmacology"},{"key":"10.1017\/S1041610218001400_bb0370","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet (London, England)"},{"key":"10.1017\/S1041610218001400_bb0375","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0380","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0385","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","article-title":"Neuroleptic sensitivity to risperidone in Lewy body dementia","volume":"346","author":"McKeith","year":"1995","journal-title":"Lancet (London, England)"},{"key":"10.1017\/S1041610218001400_bb0390","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","article-title":"Risperidone in levodopa-induced psychosis in advanced Parkinson\u2019s disease: an open-label, long-term study","volume":"12","author":"Meco","year":"1997","journal-title":"Movement Disorders"},{"key":"10.1017\/S1041610218001400_bb0395","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1017\/S1041610218001400_bb0400","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clinical Neuropharmacology"},{"key":"10.1017\/S1041610218001400_bb0405","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0410","first-page":"149","article-title":"Multiple psychopharmacological effects of the traditional Japanese Kampo Medicine Yokukansan, and the brain regions it affects","volume":"8","author":"Mizoguchi","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1017\/S1041610218001400_bb0415","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial","volume":"15","author":"Mohr","year":"2000","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0420","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clinical Neuropharmacology"},{"key":"10.1017\/S1041610218001400_bb0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","journal-title":"Annals of Neurology"},{"key":"10.1017\/S1041610218001400_bb0430","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/gps.1965","article-title":"A semi-structured interview to assess visual hallucinations in older people","volume":"23","author":"Mosimann","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0435","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1192\/bjp.175.6.576","article-title":"Active monitoring of 12, 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance","volume":"175","author":"Munro","year":"1999","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"key":"10.1017\/S1041610218001400_bb0440","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00702-014-1212-4","article-title":"Quantitative evaluation of electroconvulsive therapy for Parkinson\u2019s disease with refractory psychiatric symptoms","volume":"121","author":"Nishioka","year":"2014","journal-title":"Journal of Neural Transmission (Vienna, Austria: 1996)"},{"key":"10.1017\/S1041610218001400_bb0445","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11920-016-0730-1","article-title":"Current understanding of psychosis in Parkinson\u2019s disease","volume":"18","author":"Ojo","year":"2016","journal-title":"Current Psychiatry Reports"},{"key":"10.1017\/S1041610218001400_bb0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000316119","article-title":"Nonpharmacological therapies in Alzheimer\u2019s disease: a systematic review of efficacy","volume":"30","author":"Olazar\u00e1n","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610218001400_bb0455","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0460","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1017\/S1041610218001400_bb0465","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000107114","article-title":"Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of lewy body type","volume":"1","author":"Perry","year":"1990","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610218001400_bb0470","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","article-title":"Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness","volume":"28","author":"Perry","year":"1995","journal-title":"Brain and Cognition"},{"key":"10.1017\/S1041610218001400_bb0475","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/brainsci7070084","article-title":"Structural and functional neuroimaging of visual hallucinations in Lewy body disease: a systematic literature review","volume":"7","author":"Pezzoli","year":"2017","journal-title":"Brain Sciences"},{"key":"10.1017\/S1041610218001400_bb0480","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0485","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0490","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1017\/S1041610218001400_bb0495","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","article-title":"Epidemiology of and risk factors for psychosis of Alzheimer\u2019s disease: a review of 55 studies published from 1990 to 2003","volume":"162","author":"Ropacki","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0500","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease","volume":"14","author":"Rolinski","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610218001400_bb0505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03074779","article-title":"[Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]","volume":"37","author":"Rovers","year":"2006","journal-title":"Tijdschrift Voor Gerontologie En Geriatrie"},{"key":"10.1017\/S1041610218001400_bb0510","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1017\/S1041610218001400_bb0515","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.62.10.1601","article-title":"Delusions and hallucinations are associated with worse outcome in Alzheimer disease","volume":"62","author":"Scarmeas","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610218001400_bb0520","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00019442-200111000-00004","article-title":"National institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer disease trial methodology","volume":"9","author":"Schneider","year":"2001","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0525","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson\u2019s disease. The pramipexole study group","volume":"49","author":"Shannon","year":"1997","journal-title":"Neurology"},{"key":"10.1017\/S1041610218001400_bb0530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","article-title":"Quetiapine in the treatment of psychosis in Parkinson\u2019s disease","volume":"3","author":"Shotbolt","year":"2010","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1017\/S1041610218001400_bb0535","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bjo.2010.179465","article-title":"Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration","volume":"95","author":"Singh","year":"2011","journal-title":"The British Journal of Ophthalmology"},{"key":"10.1017\/S1041610218001400_bb0540","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","article-title":"Atypical antipsychotic use in patients with dementia: managing safety concerns","volume":"169","author":"Steinberg","year":"2012","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0545","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of Lewy body dementia: a systematic review and meta-analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0550","first-page":"CD006564","article-title":"Dopamine agonist therapy in early Parkinson\u2019s disease","volume":"16","author":"Stowe","year":"2008","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610218001400_bb0555","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease","volume":"16","author":"Streim","year":"2008","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0560","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0165-0173(88)90013-6","article-title":"Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations","volume":"13","author":"Sunderland","year":"1988","journal-title":"Brain Research Reviews"},{"key":"10.1017\/S1041610218001400_bb0565","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jagp.2015.10.007","article-title":"Visual hallucinations in eye disease and Lewy body disease","volume":"24","author":"Urwyler","year":"2016","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0570","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","article-title":"Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"86","author":"Wang","year":"2015","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0575","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","article-title":"Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis","volume":"68","author":"Weintraub","year":"2011","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610218001400_bb0580","first-page":"CD003672","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies","volume":"3","author":"Wild","year":"2003","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1017\/S1041610218001400_bb0585","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","article-title":"Visual hallucinations in the diagnosis of idiopathic Parkinson\u2019s disease: a retrospective autopsy study","volume":"4","author":"Williams","year":"2005","journal-title":"The Lancet Neurology"},{"key":"10.1017\/S1041610218001400_bb0590","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/jnnp.2007.124677","article-title":"Using the presence of visual hallucinations to differentiate Parkinson\u2019s disease from atypical parkinsonism","volume":"79","author":"Williams","year":"2008","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0595","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00019442-200002000-00010","article-title":"The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement","volume":"8","author":"Wood","year":"2000","journal-title":"The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry"},{"key":"10.1017\/S1041610218001400_bb0600","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","article-title":"The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease","volume":"9","author":"Workman","year":"1997","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1017\/S1041610218001400_bb0605","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JAD-150818","article-title":"Serotonin 2A receptor inverse agonist as a treatment for Parkinson\u2019s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators","volume":"50","author":"Yasue","year":"2016","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"key":"10.1017\/S1041610218001400_bb0610","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","article-title":"The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"190","author":"Zhao","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1017\/S1041610218001400_bb0615","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","article-title":"Ondansetron for hallucinosis in advanced Parkinson\u2019s disease","volume":"341","author":"Zoldan","year":"1993","journal-title":"The Lancet"},{"key":"10.1017\/S1041610218001400_bb0620","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224022993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224022993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610218001400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:33:24Z","timestamp":1736454804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224022993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1041610224022993"],"URL":"https:\/\/doi.org\/10.1017\/s1041610218001400","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of visual hallucinations in dementia and Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610218001400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}